Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reduction of dyskinesias and psychiatric disability with clozapine over different time courses.

Journal of psychopharmacology (Oxford, England)·2012

Same author

Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases.

Journal of the neurological sciences·2003

Same author

Ceruloplasmin immunoreactivity in neurodegenerative disorders.

Free radical research·2001

Same author

A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.

Archives of neurology·2001

Same author

The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.

Clinical neuropharmacology·2001

Same author

Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.

Movement disorders : official journal of the Movement Disorder Society·2001

Search research articles

Related Experiment Videos

Neuroprotection for Parkinson's disease.

¹Department of Neurology, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, The William Beaumont Hospital Research Institute, Royal Oak, Michigan, USA. palewitt@ameritech.net

Journal of Neural Transmission. Supplementum

|April 24, 2007

Summary

Parkinson's disease research is exploring neuroprotection strategies targeting mitochondrial defects and oxidative stress. Clinical trials are investigating new compounds to slow disease progression, with results eagerly anticipated.

Related Experiment Videos

Area of Science:

Neuroscience
Neurology
Pharmacology

Background:

Parkinson's disease (PD) etiology remains largely unknown.
Mitochondrial dysfunction and oxidative stress are implicated in PD pathogenesis.
Existing neuroprotection strategies show modest effects, necessitating further research.

Purpose of the Study:

To review current neuroprotection strategies for Parkinson's disease.
To highlight the progress and challenges in developing disease-modifying therapies for PD.
To discuss advancements in clinical trial methodologies and biomarkers for PD research.

Main Methods:

Review of existing literature on PD neuroprotection.
Analysis of clinical trial designs and outcomes.
Discussion of emerging biomarkers for assessing therapeutic efficacy.

Main Results:

Over a dozen compounds have been tested for PD disease modification.
Coenzyme Q-10 (1200mg/day) demonstrated modest clinical effects.
Advanced trial designs (staggered wash-in, factorial, futility) are enhancing research sensitivity.

Conclusions:

Despite challenges, significant efforts are underway to find effective PD neuroprotection therapies.
Biomarkers like dopaminergic neuroimaging can accelerate clinical investigations.
Upcoming trial results are expected to provide crucial insights into PD treatment.